Equities research analysts forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will post ($0.09) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings. The highest EPS estimate is $0.00 and the lowest is ($0.16). Lexicon Pharmaceuticals reported earnings of ($0.33) per share in the same quarter last year, which would indicate a positive year over year growth rate of 72.7%. The business is expected to report its next quarterly earnings results on Monday, July 29th.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($0.47) per share for the current year, with EPS estimates ranging from ($0.78) to $0.31. For the next year, analysts expect that the company will post earnings of ($0.62) per share, with EPS estimates ranging from ($1.23) to ($0.05). Zacks’ EPS averages are an average based on a survey of research firms that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $13.26 million. During the same quarter last year, the business posted ($0.40) EPS. The company’s quarterly revenue was down 63.8% compared to the same quarter last year.
Several large investors have recently made changes to their positions in the company. Gamco Investors INC. ET AL raised its position in shares of Lexicon Pharmaceuticals by 10.0% in the 1st quarter. Gamco Investors INC. ET AL now owns 22,000 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 2,000 shares in the last quarter. CWM Advisors LLC increased its position in Lexicon Pharmaceuticals by 30.2% during the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 3,030 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Lexicon Pharmaceuticals by 940.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 8,979 shares in the last quarter. Pinnacle Associates Ltd. increased its position in Lexicon Pharmaceuticals by 1.8% during the 1st quarter. Pinnacle Associates Ltd. now owns 550,549 shares of the biopharmaceutical company’s stock valued at $3,061,000 after buying an additional 9,615 shares in the last quarter. Finally, Wealth & Pension Services Group Inc. bought a new position in Lexicon Pharmaceuticals during the 1st quarter valued at approximately $60,000. 98.29% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:LXRX traded down $0.05 during trading on Friday, hitting $5.28. The stock had a trading volume of 565,251 shares, compared to its average volume of 325,812. Lexicon Pharmaceuticals has a 12 month low of $4.25 and a 12 month high of $13.13. The company has a market cap of $566.43 million, a P/E ratio of -4.63 and a beta of 0.84. The company has a fifty day moving average of $5.89.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: How Do Investors Open a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.